

PRIOR AUTHORIZATION PROGRAM FORM

Nucala™ (Mepolizumab)

Instructions:

1. Section 1 to be completed by Plan Member / Patient
2. Section 2 to be completed by Physician (expenses incurred by the completion of this form is at plan member's expense)
3. Section 3 to be completed by Pharmacist

Please fax completed form to NexgenRx Formulary Management to 1-877-639-4369 or mail to 145 The West Mall P.O. Box 110 U, Toronto, Ontario, M8Z-5M4

Section 1: To be completed by Patient

Member's Name: (Last , First)	Card ID Number:																	
Patient's Name: (Last, First)	Patient's Date of Birth (dd/mm/yy)	Relationship to Member (please circle)										PATIENT CODE						
		Employee			Spouse			Dependent										

Results of this request to be communicated to:

<input type="checkbox"/> Pharmacy	<input type="checkbox"/> Patient / Legal Guardian Named Below	<input type="checkbox"/> email:
<p>I authorize NexgenRx Inc. (a) to use the personal information disclosed on this form, and any other personal information known to NexgenRx Inc. regarding the above-named patient, for the purpose of assessing this prior authorization request and any related claim and administering the benefit plan under which any such claim is made, and (b) to contact, and to obtain any such personal information from and to disclose any such personal information to, any physician, pharmacist or other health care professional having knowledge of such patient's health relevant to this request and any related claim.</p>		
Patient / Legal Guardian Name: _____		Telephone Number: _____
Signature of Patient/ Legal Guardian: _____		Date (dd/mm/yy): _____

Section 2: To be completed by Physician

Drug Name & Strength:	DIN:	Dosage Instructions:

Eligibility for drug coverage is dependent upon the patient meeting at least one of the qualifying criteria listed below. If the patient has another drug plan, prior authorization may cover some or all of the excess not paid by the primary plan.

Please indicate if the patient meets the following qualifying criteria for drug coverage:

- Nucala is indicated as add-on maintenance treatment of adult patients with severe eosinophilic asthma who are inadequately controlled with high-dose inhaled corticosteroids and an additional asthma controller(s) (e.g. LABA), and have a blood eosinophil count of 150 cells/ugL (0.15 GI/L) at initiation of treatment with Nucala or 300 cells/ugL (0.3 GI/L) in the past 12 months.

Nucala is not indicated for other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.

Physician Name: (Last, First)	License Number:
Address: (Street, City, Province, Postal Code)	Telephone Number : () -
	Fax Number: () -
Signature of Physician:	Date (dd/mm/yy)

Section 3: To be completed by Pharmacist

Pharmacy Name:	Provider Number:
Pharmacy Address: (Street, City, Province, Postal Code)	Telephone Number : () -
	Fax Number: () -
Signature of Pharmacist: _____	
Pharmacist's Name: (Print Last, First) _____	

Internal Office Use Only:

Date Received:			Date Approved & By:
----------------	--	--	---------------------